论文部分内容阅读
目的评价药物洗脱支架(DES)对糖尿病患者冠状动脉血运重建结果的影响。方法回顾置入DES糖尿病患者的临床、冠状动脉病变与血运重建资料,并进行临床随访。结果204例糖尿病患者接受经皮冠状动脉介入治疗(PCI)时置入了一个或以上的DES,共置入316枚支架,其中DES254枚。180例患者术后接受了平均为9.3±5(6~26)个月的临床随访(随访率88.2%)。主要不良心脏事件(包括死亡、再梗死和再次血运重建)发生率为3.9%(8/204)。18例患者平均于PCI术后6.7(5.5~10)个月接受造影复查(造影随访率8.8%),经DES处理的病变无1例出现再狭窄。结论糖尿病患者使用DES安全有效,能显著降低再狭窄率和靶病变再次血运重建率。
Objective To evaluate the effect of drug-eluting stent (DES) on the results of coronary revascularization in diabetic patients. Methods The clinical data, coronary artery lesion and revascularization data of patients with DES were retrospectively reviewed and followed up. Results A total of 316 stents were placed in 204 diabetic patients undergoing percutaneous coronary intervention (PCI) with one or more DES. 180 patients received an average of 9.3 ± 5 (6 ~ 26) months of clinical follow-up (follow-up rate of 88.2%). The incidence of major adverse cardiac events (including death, reinfarction, and revascularization) was 3.9% (8/204). Eighteen patients underwent an angiographic review (angiographic follow-up of 8.8%) on average 6.7 (5.5-10) months after PCI, and none of the DES-treated lesions showed restenosis. Conclusions The use of DES in diabetic patients is safe and effective, which can significantly reduce the rate of restenosis and target revascularization again.